This trial aims not only to treat ESCS patients and dominant forms of RP linked to NR2E3 mutations, but is also trying to harness NR2E3’s potential to promote homeostasis in the degenerating retina with other forms of RP (S. Li et al., 2021b). This evidence concerns the gene NR2E3 and retinitis pigmentosa 1.